

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexascins, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/780,150	02/17/2004	David Munn	275,00090101	1273	
26813 7590 01/22/2009 MUETING, RAASCH & GEBHARDT, P.A. P.O. BOX 581336			EXAM	EXAMINER	
			THOMAS, TIMOTHY P		
MINNEAPOLIS, MN 55458-1336		ART UNIT	PAPER NUMBER		
			1614		
			MAIL DATE	DELIVERY MODE	
			01/22/2000	DADUD	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/780 150 MUNN ET AL. Office Action Summary Examiner Art Unit TIMOTHY P. THOMAS 1614 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 14 October 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)\(\times \) Claim(s) 1.2.5-7.10.17.18.20-24.26.27.43 and 97-132 is/are pending in the application. 4a) Of the above claim(s) 1.5.27 and 43 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 2,5-7,10,17,18,20-24,26 and 97-132 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Notice of Draftsporson's Fatont Drawing Proving (PTO-948)

Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _______.

Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/780,150 Page 2

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

 This application contains claims directed to the following patentably distinct species:

In addition to the previous elections required, applicant is further required to elect for each of the following species (i)-(vii):

- (i) a single method specie, from the method species recited in claims 2, 107 or 108;
- (ii) whether (claim 97, 123) or not (claim 2, 107, 108) the composition is administered before, during or after one of the therapies recited in claim 97 or 123; if a therapy of claim 97 or 123 is included in the method, applicant must also elect a single therapy specie from the therapies recited in claims 97 and 123;
- (iii) a single formulation route specie, elected from the species recited in claims 99-100 or claims 125-126;
- (iv) whether (claim 102, 128) or not (claim 99, 125) the composition is formulated for controlled or sustained release:
- (v) a single formulation specie from the species recited in claim 103 or 129;
- (vi) specify each of the formulation components present (if present) from the species recited in claims 104 and 130;
- (vii) a single tumor cell specie from the species recited in claim 106 or 132.

Application/Control Number: 10/780,150

Art Unit: 1614

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claim is generic for (i); claims 2, 98-108 and 124-132 are generic for (ii); claims 2, 6-7, 10, 17-18, 20-24, 26, 98-99, 102-125 and 128-132 are generic for (iii); claims 2, 6-7, 10, 17-18, 20-24, 26, 98-101, 103-127 and 128-132 are generic for (iv); claims 2, 6-7, 10, 17-18, 20-24, 26, 98-102, 104-128 and 130-132 are generic for (v); all claims are generic for (vi) and (vii).

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Application/Control Number: 10/780,150

Art Unit: 1614

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

2. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1614

3. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to TIMOTHY P. THOMAS whose telephone number is

(571)272-8994. The examiner can normally be reached on Monday-Thursday 6:30 a.m.

- 5:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Ardin Marschel can be reached on (571) 272-0718. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have guestions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Timothy P Thomas/ Examiner, Art Unit 1614

/Ardin Marschel/

Supervisory Patent Examiner, Art Unit 1614